B.Sc. Chemistry, First Class
PhD in Physical Chemistry
Fellow of the Royal Society of Chemistry
Member of the American Chemical Society
Fellow of the Higher Education Academy
Jeremy Everett is the Professor of Pharmaceutical Technologies at the University of Greenwich, Chatham Maritime, UK and Visiting Professor in the Faculty of Medicine at Imperial College, London. He was a Visiting Professor and Scientific Consultant in Lee Kong Chian School of Medicine at Nanyang Technological University, Singapore from 2016 to 2019 and Acting Director of the Singapore Phenome Centre (SPC). He was previously Vice President of Drug Discovery Technologies at Pfizer Global R & D with responsibility for drug target analysis, drug design, lead generation, analytical sciences, biobanking, screening file management, high throughput screening (HTS), and structural biology. He is a consultant on drug discovery to both large pharma and small research institutes and has worked as an expert witness in pharmaceutical patent litigation in the USA and Europe.
Jeremy is experienced in the application of metabolic profiling to personalized medicine, drug metabolism, toxicology and systems biology i.e. metabonomics. He is a co-inventor of pharmacometabonomics: the ability to predict drug efficacy, safety and metabolism prior to dosing by metabolic profiling (Nature 2006; PNAS 2009). Jeremy’s current research is focused on genotype to metabolic phenotype correlations in genetically modified worms, mice and humans and on the translation of a recently discovered anti-obesogenic agent to humans. He is a co-leader of the Medway Metabonomics Research Group (MMRG) at the University of Greenwich. He has over 100 publications and patents and an h-index of 31.